Menu
Not yet recruiting NCT07023744

CANnabinoids for Drug Resistant Epilepsy (DRE) in Adults and Children

Phase II Interventional Drug Resistant Epilepsy

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Placebo, CBD Isolate, CBD CHE.
Who it may be relevant to
Registry conditions: Drug Resistant Epilepsy. Basic parameters: 24 months — 55 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

A Triple-Blind, Placebo-Controlled, Randomized Clinical Trial of CANnabinoids for Drug Resistant Epilepsy in Adults and Children

Overview

Epilepsy is a neurological disorder affecting more than 50 million people globally, including more than 260,000 Canadians. Cannabidiol (CBD) reduces seizure frequency and improves quality of life for adults and children with Drug Resistant Epilepsy (DRE). Several uncontrolled, small, open label studies reported that CBD-enriched Cannabis Herbal Extract (CHE) resulted in a reduction of seizure frequency, but we lack critical information on efficacy, comparative effectiveness and dosing of CBD and ∆9-tetrahydrocannabinol (THC) in children and adults with DRE. CAN-DRE is an early phase, triple-blind, placebo-controlled, randomized clinical trial to answer the questions of if cannabinoids work to reduce seizures in children and adults (24 months to 55 years) with DRE and if CBD works better in an isolate or in a CBD-enriched Cannabis Herbal Extract. The primary outcome of CAN-DRE is reported monthly seizure count from baseline to maintenance phase.

Interventions

  • Drug Placebo
    Placebo arm: participants will receive Placebo MPL-012 oil only through the trial participation. MPL-012 is produced by MediPharm Labs, each mL contains 0mg CBD and 0mg THC.
  • Drug CBD Isolate
    CBD Isolate: MPL-015 is a CBD isolate, produced by MediPharm Labs, each mL contains 100mg CBD and 0mg THC.
  • Drug CBD CHE
    CBD-CHE arm: MPL -016 is a CBD-enriched cannabis herbal extract, produced by MediPharm Labs, each mL contains 100mg of CBD and 3mg of THC.

Primary outcome measures

  • Efficacy in reducing seizure frequency [Time frame: 116 days]
  • Cannabinoid-related AEs and DLTs [Time frame: 116 + 60 days]
Secondary outcome measures (5)
  • participant/family acceptability of this trial design [Time frame: 116 days]
  • Quality of Life reported by adult participant/family [Time frame: 116 days]
  • health resource utilization and changes [Time frame: 176 days]
  • changes in work and activity impairment affected by seizure [Time frame: 116 days]
  • Quality of Life reported by pediatric participants and family [Time frame: 116 days]

Eligibility criteria

Inclusion criteria

  • Ages 24 months to 55 years old at the time of enrollment
  • Diagnosed with DRE: not achieved seizure freedom, with adequate trials of 2 antiseizure medications 29
  • Medical history of 4 + clinically recognizable seizures (any type with clusters counted as a single event) per month
  • Have a negative pregnancy test at screening for patients who have experienced menarche
  • Agree to abstain from driving and recreational cannabis use throughout the study

Exclusion criteria

  • Diagnosis of psychogenic non-epileptic seizure
  • Recent (<30 days) change in anticonvulsant therapies including anticonvulsant medications, or settings on vagal nerve stimulator
  • Ketogenic diet started within 6 months (participants stable on the ketogenic diet for more than 6 months are eligible to participate)
  • Vagal nerve stimulator implanted and activated within 12 months
  • Concomitant regular use of narcotics (except in emergencies and physician supervised)
  • Initiation or dosage change of oral or injected steroids within 3 months
  • Allergy or intolerance to compounds in trial preparations
  • DRE secondary to progressive neurological disease
  • Clinically significant cardiac, renal or hepatic disease (as assessed by site investigator); elevated liver enzymes (GGT and/or AST and/or ALT) or lipase >3 times upper limit, adjusted for age
  • History of psychotic disorders
  • Uncontrolled (in the perspective of the qualified investigator) medical conditions including substance use disorders
  • History or concurrent cannabis use disorder
  • Unwilling or unable to use highly effective methods of contraception throughout the study period and three months post-trial, where applicable

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Quadruple blind
Primary purpose
Treatment

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT07023744 · CAN-DRE

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗